Teva Pharmaceutical Industries (NYSE: TEVA) reported earnings on Nov. 1. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Teva Pharmaceutical Industries met expectations on revenues and beat slightly on earnings per share.

Compared to the prior-year quarter, revenue grew and GAAP earnings per share dropped to a loss.

Gross margins increased, operating margins dropped, net margins dropped.

Revenue details
Teva Pharmaceutical Industries reported revenue of $4.97 billion. The 23 analysts polled by S&P Capital IQ anticipated a top line of $5.04 billion on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $4.34 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $1.28. The 25 earnings estimates compiled by S&P Capital IQ anticipated $1.25 per share. GAAP EPS were -$0.09 for Q3 against $1.03 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 52.3%, 20 basis points better than the prior-year quarter. Operating margin was -1.2%, 2,700 basis points worse than the prior-year quarter. Net margin was -1.6%, 2,270 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $5.29 billion. On the bottom line, the average EPS estimate is $1.36.

Next year's average estimate for revenue is $20.50 billion. The average EPS estimate is $5.37.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,474 members out of 2,545 rating the stock outperform, and 71 members rating it underperform. Among 542 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 537 give Teva Pharmaceutical Industries a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $50.28.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Teva Pharmaceutical Industries. Learn how to maximize your investment income and get "The 3 DOW Stocks Dividend Investors Need." Click here for instant access to this free report.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.